(lp0
S"Why Rigel Pharmaceuticals, Inc. Got Hammered Today Motley Fool - Oct 20, 2016 Rigel Pharmaceuticals  is down 23% at 11:30 a.m. EDT after the company reported a second phase 3 clinical trial testing for its spleen tyrosine kinase inhibitor, fostamatinib, in patients with adult chronic/persistent immune ...Rigel Announces Results from the Second FIT Phase 3 Study and the Long-Term ... - PR Newswire Stock Update : Here's Why Rigel Pharmaceuticals, Inc. Shares Are ... - Smarter Analyst"
p1
aS"Rigel Pharmaceuticals Inc: Hits 4-month high Times of India - Mar 8, 2017 ... ** Drug developer's shares rise as much as 14.2 pct to $2.98 - their highest intraday level since mid-November. ** Rigel on Tuesday indicates it is on track to submit a U.S. marketing application in Q1 for its experimental drug fostamatinib to ..."
p2
aS"Here's Why Rigel Pharmaceuticals, Inc. is Skyrocketing Today Motley Fool - Aug 30, 2016 What: Shareholders of Rigel Pharmaceuticals , a small-cap clinical stage biopharma, are having a pleasant Tuesday.BMO Thinks Rigel's Fostamatinib Market Opportunity Will Be Further Validated - BenzingaWhy Rigel Pharma Is Making a Run - 24/7 Wall St."
p3
aS'Why You Should Own Rigel Pharmaceuticals, Inc. Seeking Alpha - Jul 18, 2016 Rigel Pharmaceuticals Inc.  is a clinical stage biotech company with a market cap of approximately $200 million.'
p4
aS"Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing ... PR Newswire  - Jan 16, 2017 SOUTH SAN FRANCISCO, Calif., Jan. 16, 2017 /PRNewswire/ -- Rigel Pharmaceuticals  today announced that on January 3, 2017 and January 16, 2017 the Compensation Committee of Rigel's Board of Directors approved the grant of&nbsp;..."
p5
aS'Stock Returns: NewLink Genetics Corporation  versus Rigel ... CML News - 10 hours ago This is a snapshot to compare the stock returns for NewLink Genetics Corporation  versus Rigel Pharmaceuticals Inc  . The stock return points we compare look at the last three-months, six-months and twelve-months.'
p6
aS'Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year ... PR Newswire  - Feb 28, 2017 SOUTH SAN FRANCISCO, Calif., Feb. 28, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.  today announced that it will report its fourth quarter and year end 2016 financial results after market close on Tuesday, March 7, 2017.Rigel Pharmaceuticals Inc.  Moves Higher on Volume Spike for February 27 - Equities.com'
p7
aS'Earnings And Analyst Opinion Offer Spending Insights: Rigel Pharmaceuticals ... Post Analyst - 16 hours ago Rigel Pharmaceuticals, Inc.  has made its way to a 12-month gain of 45.36%. Turning to Palatin Technologies, Inc. , its shares were trading at $0.33 a retreat of $-0.01, on the trading floor.Rigel Pharmaceuticals, Inc.  Reaches $2.93 After 8.00% Up Move; Chipmos ... - Wolcott DailyTechnical Glance At Healthcare Stocks: Rigel Pharmaceuticals, Inc. (RIGL ... - TWN'
p8
aS'Rigel Pharmaceuticals Inc.  Plunges 6.99% on March 06 Equities.com - Mar 6, 2017 Rigel Pharmaceuticals Inc.  had a rough trading day for Monday March 06 as shares tumbled 6.99%, or a loss of $-0.2 per share, to close at $2.66.Rigel Pharmaceuticals Inc.: Rigel Announces Fourth Quarter 2016 and Year End ... - The Wall Street TranscriptRigel Pharmaceuticals, Inc.  Issues Quarterly Earnings Results - Chaffey Breeze'
p9
aS"Why this Peninsula biotech's layoffs aren't necessarily a bad thing (except ... San Francisco Business Times  - Sep 16, 2016 A South San Francisco company with positive results last month from a clinical trial now says it will lay off nearly four in 10 employees and part ways with its co-founder.Rigel Restructures to Focus on Fostamatinib Commercialization - PR Newswire "
p10
a.